

MDimune and SensoryCure announce a collaboration to develop therapeutics for hearing loss

SEONGDONG-GU, SEOUL, SOUTH KOREA, October 24, 2022 /EINPresswire.com/ -- MDimune, Inc., a Korean biotech company developing BioDroneTM platform technology based on cell-derived vesicles (CDVs), enters into an MOU with SensoryCure to collaborate on the development of therapeutics for hearing loss. SensoryCure is a company established by otolaryngology specialists, Dr. Bong Jik Kim (Chungnam National University Sejong Hospital, Korea) and Dr. Byung-Yoon Choi (Seoul National University Bundang Hospital, Korea) to develop



diagnostic devices and provide innovative cures for patients suffering from hearing loss.

In recent publications, Dr. Kim and Dr. Choi reported the influence of genetic contribution to pediatric mild-to-moderate hearing loss and successful long-term audiologic outcomes of cochlear implantation in patients with cochlear aplasia, which is considered one of the most severe forms of cochlear impairment. They also identified multiple genetic variants which contribute to malformation and hearing loss and established the clinical guideline to treat autoinflammatory inner ear disorder.

MDimune develops BioDrone[™] platform technology which utilizes CDVs obtained from its proprietary extrusion technology as a next-generation drug delivery system. This novel class of drug carriers is highly versatile and can be generated from various types of human cells at high production yields. The collaboration aims to demonstrate the efficacy of CDVs as a therapeutic for autoinflammatory hearing loss and commercialize the product.

Shingyu Bae, the CEO of MDimune addressed, "we have been working on the development of therapeutics for debilitating diseases. We are very excited to work with SensoryCure, the leading expert in the hearing loss field. We will also expand our research to build a gene therapy

platform in hearing loss."

Dr. Bong Jik Kim, the CEO of SensoryCure, added, "we are very pleased to collaborate with MDimune to develop therapeutics for hearing loss using their world-class technology."

Jisun Lee MDimune Inc. email us here Visit us on social media: Facebook

This press release can be viewed online at: https://www.einpresswire.com/article/597463057

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 Newsmatics Inc. All Right Reserved.